Trial Profile

A Single-arm, Open-label, Multicenter, Phase II Study for Evaluation of Efficacy and Safety of the SG001 Injection for Patients With PD-L1-positive Relapsed or Metastatic Uterine Cervical Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enlonstobart (Primary)
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Squamous cell cancer; Uterine cancer
Focus Therapeutic Use
Sponsors CSPC ZhongQi Pharmaceutical Technology

28 Jun 2024 According to CSPC Pharmaceutical media release, company announced that Enlonstobart Injection , has obtained conditional marketing approval granted by the National Medical Products Administration (NMPA) of the Peoples Republic of China.
04 Jun 2024 Results (n=107) assessing the safety and efficacy of SG001 in patients with PD-L1 positive recurrent/metastatic cervical cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
14 Nov 2021 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com